Reuters and the WSJ reported on Nov 4 that AstraZeneca offered about $10 billion, or roughly $124 a share, for the obesity drugmaker Rhythm Pharmaceuticals. Rhythm shares jumped about 28% on the news. Neither company has confirmed a deal. This resolves Yes only if either company publishes a signed, definitive agreement in a press release or SEC filing by Nov 18. Talks, rumours or a rejected bid do not count. Yes if AstraZeneca or Rhythm Pharmaceuticals officially announces a definitive deal for AstraZeneca to buy Rhythm by Nov 18, 2026 (23:59 ET).
⏱ Predict now: +27% early bonus on the base
🔥 Evet: +100% surprise bonus if correct
See what others are saying about this prediction
Reuters and the WSJ reported on Nov 4 that AstraZeneca offered about $10 billion, or roughly $124 a share, for the obesity drugmaker Rhythm Pharmaceuticals. Rhythm shares jumped about 28% on the news. Neither company has confirmed a deal. This resolves Yes only if either company publishes a signed, definitive agreement in a press release or SEC filing by Nov 18. Talks, rumours or a rejected bid do not count. Yes if AstraZeneca or Rhythm Pharmaceuticals officially announces a definitive deal for AstraZeneca to buy Rhythm by Nov 18, 2026 (23:59 ET).
⏱ Predict now: +27% early bonus on the base
🔥 Evet: +100% surprise bonus if correct
See what others are saying about this prediction